Bullous pemphigoid associated with vildagliptin
PDF (Español (España))
HTML (Español (España))

Keywords

Bullous pemphigoid
Dipeptidyl peptidase-IV inhibitors
Diabetes mellitus, type 2

How to Cite

Campbell-Silva, S. E., de la Cruz-Esparza, L., & Vásquez-Arias, F. (2021). Bullous pemphigoid associated with vildagliptin. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 7(3), 182–186. https://doi.org/10.53853/encr.7.3.631

Abstract

The prevalence of type 2 diabetes mellitus continues to increase steadily as more people live longer, and dipeptidyl peptidase-IV inhibitors, oral medications with no risk of hypoglycemia and neutral with respect to weight, become a therapeutic option for this group of elderly. However, dipeptidyl peptidase-4 inhibitors have been associated with severe skin reactions including bullous pemphigoid, and due to the morbidity and mortality associated with this condition, it is necessary to sensitize health professionals to know this link and be alert to any adverse skin reaction of these medications in at risk populations. We present two cases of bullous pemphigoid associated with vildagliptin.

https://doi.org/10.53853/encr.7.3.631
PDF (Español (España))
HTML (Español (España))

References

1. Hammers CM, Stanley JR. Mechanisms of disease: pemphigus and bullous pemphigoid. Annu Rev Pathol. 2016; 11:175-97. doi: 10.1146/annurevpathol-012615-044313.
2. Kridin K. Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations. Immunol Res. 2018;66(1):6-17. doi: 10.1007/ s12026-017-8975-2.
3. Kridin K, Ludwig RJ. The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations. Front Med (Lausanne). 2018; 5:220. doi: 10.3389/fmed.2018.00220.
4. Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas I. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol. 2012;26(2):249-53. doi: 10.1111/j.1468-3083.2011.04062.
5. Pasmatzi E, Monastirli A, Habeos J, Georgiou S, Tsambaos D. Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases. Diabetes Care. 2011;34(8): e133. doi:10.2337/dc11- 0804.
6. Agudelo-Zapata Y, Burgos-Cárdenas AJ, Díaz-Martínez AJ, Pinilla-Roa AE. Inhibidores de dipeptidil dipeptidasa-IV: de la teoría a la práctica. Rev Fac Med. 2015;63(2):259-70. doi: 10.15446/revfacmed. v63n2.48820.
7. Velásquez MM. Enfermedades ampollosas autoinmunitarias: pasado, presente y futuro. Rev. Asoc Colomb Dermatol. 2017;25(2):112-4.
8. Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl Peptidase-4 InhibitorAssociated Bullous Pemphigoid. Front Immunol. 2019; 10:1238. doi: 10.3389/fimmu.2019.01238.
9. Recursos que se convierten en salud. Descripción de las primeras descripciones realizadas a través de MIPRES 2018 [Internet]. Administradora de los Recursos del Sistema General de Seguridad Social en Salud (ADRES). Disponible en: https://bit.ly/3qKADUw.

Authors must state that they reviewed, validated and approved the manuscript's publication.  Moreover, they must sign a model release that should be sent.  A copy may be reviewed here

Dimensions


PlumX


Downloads

Download data is not yet available.